What is 89bio Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 89bio's cash to debt ratio for the quarter that ended in Mar. 2024 was 20.60.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, 89bio could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for 89bio's Cash-to-Debt or its related term are showing as below:
ETNB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 6.48 Med: 109.18 Max: No Debt
Current: 20.6
During the past 6 years, 89bio's highest Cash to Debt Ratio was No Debt. The lowest was 6.48. And the median was 109.18.
89bio Cash-to-Debt Historical Data
The historical data trend for 89bio's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
89bio Cash-to-Debt Chart
|
89bio Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
No Debt |
No Debt |
7.77 |
9.16 |
21.35 |
|
89bio Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
19.51 |
19.31 |
18.03 |
21.35 |
20.60 |
Competitive Comparison of 89bio's Cash-to-Debt
For the Biotechnology subindustry, 89bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
89bio's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 89bio's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where 89bio's Cash-to-Debt falls into.
89bio Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
89bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
89bio's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
89bio (ETNB) Business Description
Traded in Other Exchanges
N/A
Address
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Executives
| Kathleen Laporte |
director |
|
| Rohan Palekar |
director, officer: Chief Executive Officer |
201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105 |
| Atkinson Edward Morrow Iii |
director |
C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104 |
| Quoc Le-nguyen |
officer: See Remarks |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Ryan Martins |
officer: Chief Financial Officer |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Michael R Hayden |
director |
C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
| Ra Capital Healthcare Fund Lp |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Ra Capital Nexus Fund, L.p. |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Ram Waisbourd |
officer: See Remarks |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Orbimed Advisors Llc |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Gregory Grunberg |
director, 10 percent owner |
100 BEAVER STREET, WALTHAM MA 02453 |
| Anat Naschitz |
director, 10 percent owner |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Longitude Capital Partners Iii, Llc |
10 percent owner |
800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
| Lota S. Zoth |
director |
334 CR 692, BUFFALO GAP TX 79508 |
| Steven Altschuler |
director |
MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ETNB has been successfully added to your